RADX
Radiopharm Theranostics Limited
Biotechnology
Market Cap$33M
5Y Perf.-7.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RADX vs RNAZ
Revenue, margins, valuation, and 5-year total return — side by side.
RNAZ
TransCode Therapeutics, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-87.9%
RADX vs RNAZ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RADX | RNAZ |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $33M | $7M |
| Revenue (TTM) | $4M | $0.00 |
| Net Income (TTM) | $-38M | $-27M |
| Gross Margin | 1.1% | — |
| Operating Margin | -10.5% | — |
| Total Debt | $0.00 | $38K |
| Cash & Equiv. | $29M | $6M |
RADX vs RNAZ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RADX
RNAZ
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Radiopharm Theranos… (RADX) | 100 | 92.4 | -7.6% |
| TransCode Therapeut… (RNAZ) | 100 | 12.1 | -87.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RADX vs RNAZ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RADX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. TransCode Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RADX
Radiopharm Theranostics Limited
The Income Pick
RADX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.88
- -76.5% 10Y total return vs RNAZ's -100.0%
- Lower volatility, beta 0.88, current ratio 2.67x
Best for: income & stability and long-term compounding
RNAZ
TransCode Therapeutics, Inc.
The Growth Play
RNAZ is the clearest fit if your priority is growth exposure.
- EPS growth 98.6%
- -0.4% margin vs RADX's -10.6%
- -0.5% ROA vs RADX's -48.4%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RADX | 11.1% revenue growth vs RNAZ's -87.4% |
| Quality / Margins | RNAZ | -0.4% margin vs RADX's -10.6% |
| Stability / Safety | RADX | Beta 0.88 vs RNAZ's 0.95 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RADX | -4.4% vs RNAZ's -19.6% |
| Efficiency (ROA) | RNAZ | -0.5% ROA vs RADX's -48.4% |
RADX vs RNAZ — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRADXLAGGINGRNAZ
RNAZTransCode Therapeutic…
0leads
RADXRadiopharm Theranosti…
3leads
6 Total Categories
CATEGORYLEADERvs RNAZMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
RADX1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RADX4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
RADX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
RADX and RNAZ operate at a comparable scale, with $4M and $0 in trailing revenue.
| Metric | RADXRadiopharm Theran… | RNAZTransCode Therape… |
|---|---|---|
| RevenueTrailing 12 months | $4M | $0 |
| EBITDAEarnings before interest/tax | — | -$17M |
| Net IncomeAfter-tax profit | — | -$27M |
| Free Cash FlowCash after capex | — | -$15M |
| Gross MarginGross profit ÷ Revenue | +1.1% | — |
| Operating MarginEBIT ÷ Revenue | -10.5% | — |
| Net MarginNet income ÷ Revenue | -10.6% | — |
| FCF MarginFCF ÷ Revenue | -10.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | -380.7% |
Insufficient data to determine a leader in this category.
Valuation Metrics
RADX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | RADXRadiopharm Theran… | RNAZTransCode Therape… |
|---|---|---|
| Market CapShares × price | $33M | $7M |
| Enterprise ValueMkt cap + debt − cash | $12M | $896,691 |
| Trailing P/EPrice ÷ TTM EPS | -1.08x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 12.42x | — |
| Price / BookPrice ÷ Book value/share | 0.93x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RADX leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
RADX leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
RNAZ delivers a -1.9% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-109 for RADX.
| Metric | RADXRadiopharm Theran… | RNAZTransCode Therape… |
|---|---|---|
| ROE (TTM)Return on equity | -109.2% | -1.9% |
| ROA (TTM)Return on assets | -48.4% | -0.5% |
| ROICReturn on invested capital | -2.5% | — |
| ROCEReturn on capital employed | -60.6% | -5.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$29M | -$6M |
| Cash & Equiv.Liquid assets | $29M | $6M |
| Total DebtShort + long-term debt | $0 | $38,291 |
| Interest CoverageEBIT ÷ Interest expense | -584.59x | -3431.07x |
RADX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
RADX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RADX five years ago would be worth $2,349 today (with dividends reinvested), compared to $0 for RNAZ. Over the past 12 months, RADX leads with a -4.4% total return vs RNAZ's -19.6%. The 3-year compound annual growth rate (CAGR) favors RADX at -38.3% vs RNAZ's -96.3% — a key indicator of consistent wealth creation.
| Metric | RADXRadiopharm Theran… | RNAZTransCode Therape… |
|---|---|---|
| YTD ReturnYear-to-date | -19.6% | +8.1% |
| 1-Year ReturnPast 12 months | -4.4% | -19.6% |
| 3-Year ReturnCumulative with dividends | -76.5% | -100.0% |
| 5-Year ReturnCumulative with dividends | -76.5% | -100.0% |
| 10-Year ReturnCumulative with dividends | -76.5% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -38.3% | -96.3% |
RADX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RADX and RNAZ each lead in 1 of 2 comparable metrics.
Risk & Volatility
RADX is the less volatile stock with a 0.88 beta — it tends to amplify market swings less than RNAZ's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RNAZ currently trades 38.1% from its 52-week high vs RADX's 25.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RADXRadiopharm Theran… | RNAZTransCode Therape… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.88x | 0.95x |
| 52-Week HighHighest price in past year | $16.25 | $20.99 |
| 52-Week LowLowest price in past year | $3.62 | $6.08 |
| % of 52W HighCurrent price vs 52-week peak | +25.5% | +38.1% |
| RSI (14)Momentum oscillator 0–100 | 41.3 | 31.2 |
| Avg Volume (50D)Average daily shares traded | 184K | 8K |
Evenly matched — RADX and RNAZ each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | RADXRadiopharm Theran… | RNAZTransCode Therape… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RADX leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.
Best OverallRadiopharm Theranostics Lim… (RADX)Leads 3 of 6 categories
Loading custom metrics...
RADX vs RNAZ: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — RADX or RNAZ?
Over the past 5 years, Radiopharm Theranostics Limited (RADX) delivered a total return of -76.
5%, compared to -100. 0% for TransCode Therapeutics, Inc. (RNAZ). Over 10 years, the gap is even starker: RADX returned -76. 5% versus RNAZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — RADX or RNAZ?
By beta (market sensitivity over 5 years), Radiopharm Theranostics Limited (RADX) is the lower-risk stock at 0.
88β versus TransCode Therapeutics, Inc. 's 0. 95β — meaning RNAZ is approximately 8% more volatile than RADX relative to the S&P 500.
03Which is growing faster — RADX or RNAZ?
On earnings-per-share growth, the picture is similar: TransCode Therapeutics, Inc.
grew EPS 98. 6% year-over-year, compared to 85. 3% for Radiopharm Theranostics Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — RADX or RNAZ?
TransCode Therapeutics, Inc.
(RNAZ) is the more profitable company, earning 0. 0% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNAZ leads at 0. 0% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — RADX leads at 1. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — RADX or RNAZ?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is RADX or RNAZ better for a retirement portfolio?
For long-horizon retirement investors, Radiopharm Theranostics Limited (RADX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
88)). Both have compounded well over 10 years (RADX: -76. 5%, RNAZ: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between RADX and RNAZ?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RADX is a small-cap high-growth stock; RNAZ is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.